Drug or treatment

Depemokimab clinical trials

• 7Clinical trials
• 36Countries

Newest trials

All recruiting trials (7)

• Depemokimab monotherapy for chronic rhinosinusitis with nasal polyps in Japanese adults

  This study tests depemokimab alone (without intranasal corticosteroids) in adults with chronic rhinosinusitis with nasal polyps in Japan.

  Recruiting at 10 sites Phase 4 GlaxoSmithKline · Ehime and 9 other locations · NCT07701967

• Depemokimab in children aged 6 to 11 with asthma and type-2 inflammation

  This trial tests depemokimab as an add-on treatment for kids 6 to 11 with asthma and type-2 inflammation to see how the drug behaves in the body and whether it is safe and tolerable.

  Recruiting at 3 sites Phase 3 GlaxoSmithKline · Mobile, Alabama and 2 other locations · NCT07671001

• Depemokimab added to standard care in adults and adolescents with Type 2 asthma at risk of flare-ups

  This study tests whether adding depemokimab to usual asthma care can reduce worsening episodes in people with Type 2 asthma who have had recent flare-ups.

  Recruiting at 17 sites Phase 3 GlaxoSmithKline · Little Rock, Arkansas and 16 other locations · NCT07456033

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

• Depemokimab imaging and bronchoscopy for eosinophilic asthma

  This trial tests whether depemokimab changes lung structure and function in people with eosinophilic (Type 2) asthma using HRCT and bronchoscopy.

  Recruiting at 49 sites Phase 3 GlaxoSmithKline · Brooksville, Florida and 49 other locations · NCT06979323

• Depemokimab for adults with COPD and eosinophilic (type 2) inflammation

  This study will test whether adding depemokimab to usual inhaled therapy can reduce flare-ups and improve outcomes for adults (40–80) with moderate-to-severe COPD and high blood eosinophils.

  Recruiting at 193 sites Phase 3 GlaxoSmithKline · Sheffield, Alabama and 192 other locations · NCT06961214

• Depemokimab — a long‑acting biologic for adults with COPD and type 2 inflammation.

  This trial will test whether adding depemokimab, a long‑acting injectable biologic, reduces flare-ups and improves symptoms in adults with uncontrolled moderate-to-severe COPD who have type 2 inflammation.

  Recruiting at 281 sites Phase 3 GlaxoSmithKline · Bakersfield, California and 280 other locations · NCT06959095

Quick answers

How many clinical trials of Depemokimab are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 36 countries. The most sites are in United States (6 trials), United Kingdom (4 trials), Germany (4 trials), Greece (3 trials), Canada (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →